Europe — EMA
Orfiril Retard (Sodium Valproate)
Sodium Valproate, the active ingredient in Orfiril Retard, is an anticonvulsant presented as a prolonged-release tablet for oral use. It is used to manage certain seizure types and mood disorders in adults and children.
Request sourcing
What is Sodium Valproate?
Sodium Valproate, the active ingredient in Orfiril Retard, is an anticonvulsant presented as a prolonged-release tablet for oral use. It is used to manage certain seizure types and mood disorders in adults and children. GNH USA supplies Orfiril Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
GNH USA supplies Orfiril Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Sodium Valproate used for?
Orfiril Retard is an anticonvulsant that acts on neuronal excitability in various neurological conditions.
- Epilepsy: Helps control generalized tonic‑clonic seizures and focal seizures. - Bipolar disorder: Provides mood stabilization for patients with manic episodes. - Migraine prophylaxis: Reduces frequency of migraine attacks when other treatments are insufficient.
What are the side effects of Sodium Valproate?
Adverse reactions to sodium valproate may vary in frequency and severity.
Common Side Effects: - Nausea and vomiting - Tremor - Weight gain - Hair loss - Drowsiness - Elevated liver enzymes
Serious or Rare Side Effects: - Severe liver injury - Pancreatitis - Thrombocytopenia - Hyperammonemia - Stevens‑Johnson syndrome - Aplastic aplastic bone marrow failure.
What precautions apply to Sodium Valproate?
Patients should consider several g t ... ... ... ... t d d \n
